Fig. 4
POSTN overexpression may contribute to enhanced malignancy and resistance to temozolomide, thereby corroborating its involvement in cancer processes. A, Immunofluorescence illustrating the efficiency of POSTN overexpression lentiviral transduction in the control (EV group) and POSTN group. B, Western blot analysis of POSTN protein expression in LN229 cells with or without POSTN overexpression lentivirus transduction, using GAPDH as the internal control. C, qRT-PCR analysis of POSTN mRNA levels in LN229 cells following POSTN lentiviral transduction (****P < 0.0001, Student’s t-test). D, EDU staining of LN229 cells with or without POSTN overexpression lentiviral transduction. Microscopic counts of EDU-positive cell clones represent proliferation ability (**P < 0.01, Student’s t-test). E, In vitro proliferation assay of LN229 cells with lentiviral POSTN or control transduction (**P < 0.01, one-way ANOVA followed by Dunnett’s post-test). F, Wound healing assays on LN229 cells transduced with POSTN overexpression lentivirus or control at day 0 (top) and day 3 (bottom). The migration distance was significantly increased in the POSTN-overexpressing group compared to the control group (*P < 0.05, Student’s t-test). G, Invasion assays of LN229 cells transfected with POSTN lentivirus or control (**P < 0.01, Student’s t-test). H, Colony formation assays of LN229 cells transfected with or without POSTN overexpression lentivirus (**P < 0.01, Student’s t-test). I, Cytotoxicity assays of LN229 cells transfected with POSTN lentivirus or control (**P < 0.01, one-way ANOVA followed by Dunnett’s post-test). J, In vivo bioluminescence imaging of POSTN-overexpressing LN229 cells at week 1 (top) and week 4 (bottom). The bar graph quantified the mean fluorescence intensity ratio at 4 weeks relative to 1 week (**P < 0.01, one-way ANOVA followed by Dunnett’s post-test).
